JPRN-UMIN000006547已完成2 期
Phase II study of q3w nab-paclitaxel in combination with q3w trastuzumab for HER2 positive metastatic breast cancer. - Nature study
Fukushima Medical University School of medicine0 个研究点目标入组 35 人开始时间: 2011年10月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. With history of hypersensitivity reaction for paclitaxel and/or albumin and/or trastuzumab. 2. With severe complications. 3. Pregnant or nursing women. 4. With widespread liver metastases or with dyspnea in pulmonary lymphangitis. 5. With severe complications. 6. With brain metastasis. 7. with uncontrollable hypertension, angina, congestive heart failure, myocardial infection within 1 year, arrhythmia, valvular heart disease. 8. With pulmonary fibrosis or pneumonitis. 9. With dyspnea at rest. 10. With pleural effusion, ascites, pericardial effusion. 11. Doctor's decision not to be registered to this study.
研究者
相似试验
招募中
2 期
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
已完成
2 期
PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancerBreast cancerJPRN-UMIN000022931Rakuwakai Otowa Hospital Breast oncology department24
招募中
2 期
Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer who have failed prior chemotherapyMetastatic and Recurrenced Breast CancerJPRN-UMIN000009153Toho University Omori Medical Center20
招募中
2 期
Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancerJPRN-UMIN000006427Toho University Omori Medical Center40
已完成
不适用
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30